JP2009524692A - ドライアイのための処方物および方法 - Google Patents

ドライアイのための処方物および方法 Download PDF

Info

Publication number
JP2009524692A
JP2009524692A JP2008552581A JP2008552581A JP2009524692A JP 2009524692 A JP2009524692 A JP 2009524692A JP 2008552581 A JP2008552581 A JP 2008552581A JP 2008552581 A JP2008552581 A JP 2008552581A JP 2009524692 A JP2009524692 A JP 2009524692A
Authority
JP
Japan
Prior art keywords
eye
registered trademark
subject
ophthalmic formulation
tear
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008552581A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009524692A5 (enExample
Inventor
ジョージ ダブリュー． ウースラー，
マシュー ジェイ． チャピン，
マーク ビー． アベルソン，
Original Assignee
アーシエックス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アーシエックス， インコーポレイテッド filed Critical アーシエックス， インコーポレイテッド
Publication of JP2009524692A publication Critical patent/JP2009524692A/ja
Publication of JP2009524692A5 publication Critical patent/JP2009524692A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2008552581A 2006-01-25 2007-01-25 ドライアイのための処方物および方法 Pending JP2009524692A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76194506P 2006-01-25 2006-01-25
PCT/US2007/061065 WO2007087609A2 (en) 2006-01-25 2007-01-25 Formulations and methods for treating dry eye

Publications (2)

Publication Number Publication Date
JP2009524692A true JP2009524692A (ja) 2009-07-02
JP2009524692A5 JP2009524692A5 (enExample) 2011-03-17

Family

ID=38309951

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008552581A Pending JP2009524692A (ja) 2006-01-25 2007-01-25 ドライアイのための処方物および方法

Country Status (6)

Country Link
US (1) US20070254841A1 (enExample)
EP (1) EP1981491A4 (enExample)
JP (1) JP2009524692A (enExample)
AU (1) AU2007208054A1 (enExample)
CA (1) CA2636646A1 (enExample)
WO (1) WO2007087609A2 (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011513416A (ja) * 2008-03-03 2011-04-28 アラーガン、インコーポレイテッド 眼痛を処置または防止するためのケトロラックトロメタミン組成物
JP2013503873A (ja) * 2009-09-01 2013-02-04 アラーガン インコーポレイテッド 眼痛を処置または予防するためのケトロラクトロメタミン組成物
JP2014510018A (ja) * 2010-12-15 2014-04-24 シェンヤン、シンチ、ファーマシューティカル、カンパニー、リミテッド ブロムフェナク有機塩、ならびにその製造方法、組成物および使用
JP2014513073A (ja) * 2011-04-05 2014-05-29 オプトソルヴ リミテッド ライアビリティー パートナーシップ 眼科治療
JP2014521606A (ja) * 2011-07-22 2014-08-28 インサイト・ビジョン・インコーポレイテッド 眼表面アレルギーの処置のための組成物および方法
JP2020122009A (ja) * 2013-12-25 2020-08-13 株式会社Ｌｔｔバイオファーマ ドライアイ治療用点眼剤

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1654002B2 (en) * 2003-08-07 2014-01-29 Allergan, Inc. Compositions for delivery of therapeutics into the eyes
US8748402B2 (en) 2004-06-07 2014-06-10 Bausch & Lomb Pharma Holdings Corp. Ophthalmic formulations and uses thereof
US8372814B2 (en) * 2004-06-07 2013-02-12 Ista Pharmaceuticals, Inc. Ophthalmic formulations and uses thereof
US8137111B2 (en) * 2007-06-28 2012-03-20 Eye Care And Cure Pte. Ltd Model human eye
AU2009202969B1 (en) * 2009-07-23 2009-11-19 Allergan, Inc. Ketorolac tromethamine compositions for treating or preventing ocular pain
US8778999B2 (en) 2009-03-05 2014-07-15 Insite Vision Incorporated Non-steroidal anti-inflammatory ophthalmic compositions
HUE038821T2 (hu) 2009-12-03 2018-11-28 Novartis Ag Karboxivinil polimert tartalmazó nanorészecske szuszpenziók
AU2011237646A1 (en) * 2010-04-09 2012-11-08 Allergan, Inc. Ketorolac compositions for corneal wound healing
US8684743B2 (en) 2010-07-23 2014-04-01 Eye Care And Cure Pte. Ltd Model human eye and face manikin for use therewith
WO2014207769A1 (en) 2013-06-27 2014-12-31 Mylan Laboratories Ltd Process for the preparation of nepafenac
PT3613423T (pt) 2013-07-10 2022-12-07 Matrix Biology Inst Composições de hialuronano de elevada elasticidade e suas utilizações
US9775796B1 (en) * 2014-09-26 2017-10-03 Paul S. Jensen Dry skin composition and method for preparing the composition
PT3352766T (pt) 2015-09-24 2022-03-22 Matrix Biology Inst Composições de hialuronano de elevada elasticidade e processos para o seu uso
WO2023280319A1 (zh) * 2021-07-09 2023-01-12 广州润尔眼科生物科技有限公司 洛索洛芬钠在制备治疗干眼的药物中的应用
EP4472622A4 (en) * 2022-02-01 2026-01-14 Baylor College Medicine RXR AGONISTS IN EYE DISORDERS

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050239745A1 (en) * 2004-03-03 2005-10-27 Ophthalmic Research Associates, Inc. Novel topical ophthalmic formulations
WO2005101982A2 (en) * 2004-03-24 2005-11-03 Sun Pharmaceutical Industries Limited A stable ophthalmic composition

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4230724A (en) * 1979-07-16 1980-10-28 Allergan Pharmaceuticals, Inc. Method of treating vascularization of the eye with Flurbiprofen
US4407791A (en) * 1981-09-28 1983-10-04 Alcon Laboratories, Inc. Ophthalmic solutions
US4454151A (en) * 1982-03-22 1984-06-12 Syntex (U.S.A.) Inc. Use of pyrrolo pyrroles in treatment of ophthalmic diseases
DE3612537C1 (de) * 1986-04-14 1987-07-16 Dispersa Ag Arzneimittel zur Behandlung von Entzuendungen im Auge
US5110493A (en) * 1987-09-11 1992-05-05 Syntex (U.S.A.) Inc. Ophthalmic NSAID formulations containing a quaternary ammonium preservative and a nonionic surfactant
US4910225A (en) * 1988-01-27 1990-03-20 Senju Pharmaceutical Co., Ltd. Locally administrable therapeutic composition for inflammatory disease
US4960799A (en) * 1988-09-13 1990-10-02 Ciba-Geigy Corporation Stabilized aqueous solutions of pharmaceutically acceptable salts of ortho-(2,6-dichlorophenyl)-aminophenylacetic acid for opthalmic use
BR9307541A (pt) * 1992-11-27 1999-06-01 Siemens Ag Ligação de plugue para um guia de luz que pode ser conectado a um quadro de modulação
US5475034A (en) * 1994-06-06 1995-12-12 Alcon Laboratories, Inc. Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders
US5811446A (en) * 1997-04-18 1998-09-22 Cytos Pharmaceuticals Llc Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor
DE69818675T2 (de) * 1997-07-29 2004-07-29 Alcon Laboratories, Inc., Fort Worth Galaktomannanpolymere und borat enthaltende augenarzneimittel
US6552020B1 (en) * 1999-07-30 2003-04-22 Allergan, Inc. Compositions including antibiotics and methods for using same
JP2005521690A (ja) * 2002-02-22 2005-07-21 ファルマシア・コーポレーション ゴム系を含む眼科用製剤
US6806364B2 (en) * 2002-07-29 2004-10-19 Ast Products, Inc. Ophthalmic compositions
US6828356B2 (en) * 2002-07-29 2004-12-07 Ast Products, Inc. Preparation of ophthalmic compositions
WO2004064828A1 (ja) * 2003-01-21 2004-08-05 Senju Pharmaceutical Co., Ltd. ２−アミノ−３−(４−ブロモベンゾイル)フェニル酢酸含有水性液剤
SI1885336T1 (sl) * 2005-05-10 2009-08-31 Alcon Inc Suspenzijske formulacije, ki obsegajo aktivno sestavino, poloksamerni ali meroksapolni surfaktant in glikol, in njihova uporaba za pripravo zdravila za zdravljenje oftalmičnih motenj

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050239745A1 (en) * 2004-03-03 2005-10-27 Ophthalmic Research Associates, Inc. Novel topical ophthalmic formulations
WO2005101982A2 (en) * 2004-03-24 2005-11-03 Sun Pharmaceutical Industries Limited A stable ophthalmic composition

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN5010008247; ＬＥＫＨＡＮＯＮＴ　ＫＡＥＶＡＬＩＮ: ＪＯＵＲＮＡＬ　ＯＦ　ＯＣＵＬＡＲ　ＰＨＡＲＭＡＣＯＬＯＧＹ　ＡＮＤ　ＴＨＥＲＡＰＥＵＴＩＣＳ Ｖ２３　Ｎ１, 20070201, Ｐ２７-３４, ＭＡＲＹ　ＡＮＮ　ＬＩＥＢＥＲＴ　ＩＮＣ． *
JPN6012019223; ＧＩＯＲＧＩ，　Ｄ．　ｅｔ　ａｌ．: ＲＥＣＥＮＴＩ　ＰＲＯＧＲＥＳＳＩ　ＩＮ　ＭＥＤＩＣＩＮＡ Ｖｏｌ．８８，　Ｎｏ．９, 1997, ｐｐ．３９７-４００ *
JPN6012019226; ＲＯＬＡＮＤＯ，　Ｍ．　ｅｔ　ａｌ．: Ａｄｖａｎｃｅｓ　ｉｎ　Ｅｘｐｅｒｉｍｅｎｔａｌ　Ｍｅｄｉｃｉｎｅ　ａｎｄ　Ｂｉｏｌｏｇｙ Ｖｏｌ．５０６，　Ｐａｒｔ．Ｂ, 2002, ｐｐ．１２３７-１２４０ *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011513416A (ja) * 2008-03-03 2011-04-28 アラーガン、インコーポレイテッド 眼痛を処置または防止するためのケトロラックトロメタミン組成物
JP2013503873A (ja) * 2009-09-01 2013-02-04 アラーガン インコーポレイテッド 眼痛を処置または予防するためのケトロラクトロメタミン組成物
JP2014510018A (ja) * 2010-12-15 2014-04-24 シェンヤン、シンチ、ファーマシューティカル、カンパニー、リミテッド ブロムフェナク有機塩、ならびにその製造方法、組成物および使用
JP2014513073A (ja) * 2011-04-05 2014-05-29 オプトソルヴ リミテッド ライアビリティー パートナーシップ 眼科治療
JP2017141243A (ja) * 2011-04-05 2017-08-17 オプトソルヴ リサーチ アンド ディベロップメント リミテッド 眼科治療
JP2014521606A (ja) * 2011-07-22 2014-08-28 インサイト・ビジョン・インコーポレイテッド 眼表面アレルギーの処置のための組成物および方法
JP2020122009A (ja) * 2013-12-25 2020-08-13 株式会社Ｌｔｔバイオファーマ ドライアイ治療用点眼剤

Also Published As

Publication number Publication date
US20070254841A1 (en) 2007-11-01
EP1981491A4 (en) 2009-09-23
EP1981491A2 (en) 2008-10-22
WO2007087609A3 (en) 2007-11-29
AU2007208054A1 (en) 2007-08-02
CA2636646A1 (en) 2007-08-02
WO2007087609A2 (en) 2007-08-02

Similar Documents

Publication Publication Date Title
US20070254841A1 (en) Formulations and methods for treating dry eye
JP7088980B2 (ja) セチリジンの眼科用製剤および使用方法
US20100311688A1 (en) Ophthalmic formulations, methods of manufacture, and methods of using same
US20070297981A1 (en) Formulations and methods for treating dry eye
US20090010850A1 (en) Formulations and methods for treating dry eye
US20120021072A1 (en) Compositions For The Treatment And Prevention Of Eyelid Swelling
JP2012520880A (ja) ケトチフェンの眼科用製剤および使用方法
US20210177807A1 (en) Compositions for the treatment and prevention of eyelid swelling
US20080039398A1 (en) Formulations and methods for treating dry eye
CA2705050A1 (en) Compositions for the treatment and prevention of eyelid swelling
JP2013522312A (ja) セチリジンの眼用製剤、および使用方法
US20070299124A1 (en) Formulations and methods for treating dry eye
JP2017014294A (ja) 安定で保存剤非含有の散瞳および抗炎症注射用液剤
US20050239745A1 (en) Novel topical ophthalmic formulations
US20100130580A1 (en) Formulations and Methods for Treating Dry Eye

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100121

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110114

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120416

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120713

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120717

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120723

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120724

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130115